Implantica publishes Interim Report January - June 2025 (Q2)

Significant events in the second quarter of 2025 Significant events in the second quarter of 2025 Significant events after the end of the period Financial summary second quarter 2025 First six months Telephone conference Implantica will hold a teleconference on14 August 2025at 15:00 (CEST) withPeter Forsell(CEO), Andreas Öhrnberg (CFO), andNicole Pehrsson(Chief Corporate Affairs Officer). Please see the dial-in details below to join the conference: ...

VADUZ, 14/08/2025 (informazione.news - comunicati stampa - salute e benessere)

Implantica will hold a teleconference on 14 August 2025 at 15:00 (CEST) with Peter Forsell (CEO), Andreas Öhrnberg (CFO), and Nicole Pehrsson (Chief Corporate Affairs Officer). Please see the dial-in details below to join the conference:

Webcast

If you wish to participate via webcast, please use the following link:

https://implantica.events.inderes.com/q2-report-2025

Dial-in

Dial-in numbers to the teleconference will be received by registering on the link below. After the registration, you will be provided phone numbers and a conference ID to access the conference.

https://conference.inderes.com/teleconference/?id=5009464

Nicole Pehrsson , Chief Corporate Affairs Officer
Telephone (CH): +41 (0)79 335 09 49
nicole.pehrsson@implantica.com

Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm .

The company's Certified Adviser is FNCA Sweden AB, info@fnca.se

Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica's lead product, RefluxStop , is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further information.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/implantica/r/implantica-publishes-interim-report-january---june-2025--q2-,c4217816

The following files are available for download:

 

View original content:https://www.prnewswire.co.uk/news-releases/implantica-publishes-interim-report-january--june-2025-q2-302529881.html